Multimarker prediction of coronary heart disease risk: the Women's Health Initiative.

[1]  L. Wallentin,et al.  Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. , 2009, Journal of the American College of Cardiology.

[2]  M. Pencina,et al.  Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. , 2009, JAMA.

[3]  J. Liao,et al.  Genetically elevated C-reactive protein and ischemic vascular disease , 2009, Current atherosclerosis reports.

[4]  D. Lawlor,et al.  Interleukin-6 and incident coronary heart disease: results from the British Women's Heart and Health Study. , 2009, Atherosclerosis.

[5]  L. Smeeth,et al.  Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. , 2009, International journal of epidemiology.

[6]  L. Irwig,et al.  Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide. , 2008, Archives of internal medicine.

[7]  Holly Janes,et al.  Assessing the Value of Risk Predictions by Using Risk Stratification Tables , 2008, Annals of Internal Medicine.

[8]  Jennifer G. Robinson,et al.  Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. , 2008, Archives of internal medicine.

[9]  N. Paynter,et al.  C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men , 2008, Circulation.

[10]  J. Sundström,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes , 2008 .

[11]  P. Whincup,et al.  Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. , 2008, QJM : monthly journal of the Association of Physicians.

[12]  R. Klein,et al.  Risk prediction of coronary heart disease based on retinal vascular caliber (from the Atherosclerosis Risk In Communities [ARIC] Study). , 2008, The American journal of cardiology.

[13]  J. Manson,et al.  Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. , 2008, The American journal of cardiology.

[14]  D. Lloyd‐Jones,et al.  Multiple biomarker panels for cardiovascular risk assessment. , 2008, The New England journal of medicine.

[15]  Vilmundur Gudnason,et al.  Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review , 2008, PLoS medicine.

[16]  J. Manson,et al.  Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. , 2008, Atherosclerosis.

[17]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[18]  J. Danesh,et al.  Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. , 2007, European heart journal.

[19]  M. Woodward,et al.  A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease , 2007, Journal of thrombosis and haemostasis : JTH.

[20]  Fred S Apple,et al.  National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. , 2007, Circulation.

[21]  N. Cook.  Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[22]  N. Cook,et al.  Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.

[23]  Paul M. Ridker,et al.  Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women , 2007 .

[24]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[25]  J. Ware.  The limitations of risk factors as prognostic tools. , 2006, The New England journal of medicine.

[26]  P. Ridker,et al.  The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. , 2006, Journal of the American College of Cardiology.

[27]  Eric Boerwinkle,et al.  An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. , 2006, Archives of internal medicine.

[28]  Nancy R Cook,et al.  The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women , 2006, Annals of Internal Medicine.

[29]  J. Manson,et al.  Conjugated equine estrogens and coronary heart disease : The women's health initiative , 2006 .

[30]  D. Lawlor,et al.  Cardiovascular disease risk assessment in older women: can we improve on Framingham? British Women’s Heart and Health prospective cohort study , 2006, Heart.

[31]  P. Venge,et al.  Troponin I as a Predictor of Coronary Heart Disease and Mortality in 70-Year-Old Men: A Community-Based Cohort Study , 2006, Circulation.

[32]  N. Wald,et al.  The efficacy of combining several risk factors as a screening test , 2005, Journal of medical screening.

[33]  M. Pencina,et al.  C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. , 2005, Archives of internal medicine.

[34]  G. Lowe,et al.  Which Hemostatic Markers Add to the Predictive Value of Conventional Risk Factors for Coronary Heart Disease and Ischemic Stroke?: The Caerphilly Study , 2005, Circulation.

[35]  H Tunstall-Pedoe,et al.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.

[36]  G. Dagenais,et al.  Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study. , 2005, Atherosclerosis.

[37]  G. Lowe.  Circulating inflammatory markers and risks of cardiovascular and non‐cardiovascular disease , 2005, Journal of thrombosis and haemostasis : JTH.

[38]  D. Siscovick,et al.  Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.

[39]  J. Manson,et al.  Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. , 2005, Archives of internal medicine.

[40]  Va Medical.  Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors , 2005 .

[41]  Imran Awan,et al.  Leukocyte count and coronary heart disease: implications for risk assessment. , 2004, Journal of the American College of Cardiology.

[42]  G. Lowe,et al.  Interleukin-6, Fibrin D-Dimer, and Coagulation Factors VII and XIIa in Prediction of Coronary Heart Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[43]  D. Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death , 2004 .

[44]  M. Pepe,et al.  Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. , 2004, American journal of epidemiology.

[45]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[46]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[47]  C. Meisinger,et al.  C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score: Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany , 2004, Circulation.

[48]  J. Danesh,et al.  Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. , 2004, European heart journal.

[49]  M. Puato,et al.  C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? , 2003, Journal of hypertension.

[50]  Scott Davis,et al.  Implementation of the Women's Health Initiative study design. , 2003, Annals of epidemiology.

[51]  C. Kooperberg,et al.  Outcomes ascertainment and adjudication methods in the Women's Health Initiative. , 2003, Annals of epidemiology.

[52]  A. Folsom,et al.  Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. , 2003, Journal of clinical epidemiology.

[53]  Mary Cushman,et al.  Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.

[54]  A. Hofman,et al.  The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. , 2003, Archives of internal medicine.

[55]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[56]  Per Magne Ueland,et al.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. , 2002, JAMA.

[57]  J. Manson,et al.  Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. , 2002, JAMA.

[58]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[59]  A. Mangoni,et al.  Homocysteine and cardiovascular disease: current evidence and future prospects. , 2002, The American journal of medicine.

[60]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[61]  J. Danesh,et al.  Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis , 2001, The Lancet.

[62]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[63]  J. Danesh,et al.  Fibrin D-Dimer and Coronary Heart Disease: Prospective Study and Meta-Analysis , 2001, Circulation.

[64]  V. Salomaa,et al.  Prospective Study of Fibrinolytic Factors and Incident Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[65]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[66]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[67]  P. Savage,et al.  The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[68]  A. Sharrett,et al.  Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[69]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[70]  P M Rautaharju,et al.  The Novacode criteria for classification of ECG abnormalities and their clinically significant progression and regression. , 1998, Journal of electrocardiology.

[71]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[72]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[73]  A. Folsom,et al.  Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. , 1997, Circulation.

[74]  G. T. Jones.  Blood platelet count and function are related to total and cardiovascular death in apparently healthy men , 1992 .

[75]  J V Castell,et al.  Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.

[76]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[77]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.